Atea Pharmaceuticals Appoints Polly Murphy, D.V.M, Ph.D., to the Board of Directors

Pharmaceutical executive brings 20 years of clinical, commercial and operational leadership BOSTON, Mass., September 14, 2020 – Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next- generation therapeutics for severe viral infections, today announced the appointment of Polly Murphy, D.V.M., Ph.D., Chief Business Officer of UroGen Pharma, to its Board […]

Atea Pharmaceuticals Strengthens Management Team with Appointment of Clinical and Regulatory Leadership

Executive Vice President of Clinical Sciences and Vice President of Regulatory Bring Decades of Clinical and Regulatory Experience BOSTON, Mass., August 24, 2020 – Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced the appointments of Arantxa Horga, M.D., as Executive Vice President […]

Atea Pharmaceuticals Appoints Janet Hammond, M.D., Ph.D., as Chief Development Officer

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced the appointment of Janet Hammond, M.D., Ph.D., Sc.M., F.C.P., to the newly-created position of Chief Development Officer. Dr. Hammond will be responsible for overseeing Atea’s clinical development programs, specifically spearheading its development of AT-527 for the treatment of COVID-19.

Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced a $215 million Series D financing. The financing was led by Bain Capital Life Sciences and also included new investors RA Capital Management, Perceptive Advisors, Rock Springs Capital, Adage Capital Management, Redmile Group, Omega Funds, and funds and accounts managed by T. Rowe Price Associates, Inc.

Atea Pharmaceuticals to present positive clinical data with AT-527 for the treatment of chronic Hepatitis C in patients with cirrhosis at The Liver Meeting® 2018

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today announced it will present positive data from its recently completed Phase IB/IIA trial of AT-527 in treatment-naïve HCV-infected patients, including HCV-infected patients with Child-Pugh A (CPA) cirrhosis.

Atea Pharmaceuticals reports positive proof of concept clinical data with AT-527 for the treatment of chronic Hepatitis C

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced the appointment of Janet Hammond, M.D., Ph.D., Sc.M., F.C.P., to the newly-created position of Chief Development Officer. Dr. Hammond will be responsible for overseeing Atea’s clinical development programs, specifically spearheading its development of AT-527 for the treatment of COVID-19.

AT-527, a Purine Nucleotide Prodrug, Exhibits Potent Pan-Genotypic Antiviral Activity in HCV-Infected Subjects with Cirrhosis

Presented at The 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, November 9-13, 2018

AT-527, a Pan-Genotypic Purine Nucleotide Prodrug, Exhibits Potent Antiviral Activity in Subjects with Chronic Hepatitis C

Presented at The International Liver Congress™ 2018 (ILC 2018), the 53rd Annual Meeting of the European Association for the Study of the Liver (EASL), Paris, France, April 11-15, 2018

A Phase 1a Study of AT-527, a Novel Pan-Genotypic Purine Nucleotide Prodrug Inhibitor of Hepatitis C Virus (HCV)

Presented at The 68th Annual Meeting of the American Association for the Study of Liver diseases (AASLD), Washington DC, October 20-24, 2017

AT-337, AT-511 and its Salt Form, AT-527: Novel Potent and Selective Pan-Genotypic Purine Nucleotide Prodrug Inhibitors of HCV Polymerase

Presented at The 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA, November 11-15, 2016